Srinagar Magazine

Cytokine Release Syndrome Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight

 Breaking News
  • No posts were found

Cytokine Release Syndrome Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight

January 17
17:48 2023
Cytokine Release Syndrome Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight
Cytokine Release Syndrome Pipeline Insights
DelveInsight’s, “Cytokine Release Syndrome – Pipeline Insight, 2023,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Cytokine Release Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight’s Cytokine Release Syndrome Pipeline Insight 2023 report provides comprehensive global coverage of available, marketed, and pipeline Cytokine Release Syndrome therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Cytokine Release Syndrome pipeline domain.

Key Takeaways from the Cytokine Release Syndrome Pipeline Report

  • Over 5+ Cytokine Release Syndrome pipeline therapies are in various stages of development, and their anticipated acceptance in the Cytokine Release Syndrome market would significantly increase market revenue. 
  • Leading Cytokine Release Syndrome companies developing novel drug candidates to improve the Cytokine Release Syndrome treatment landscape include Novartis, Incyte Corporation, Olatec Therapeutics LLC, and others.
  • Promising Cytokine Release Syndrome pipeline therapies in various stages of development include Canakinumab, Itacitinib, Dapansutrile, and others.

Cytokine Release Syndrome Overview

Cytokine release syndrome (CRS) happens when your immune system responds more aggressively to infection or immunotherapy drugs than it should. CRS symptoms include fever, nausea, fatigue and body aches. Prompt treatment is essential, as symptoms can worsen quickly.

Cytokine Release Syndrome Pipeline Analysis: Drug Profile

Canakinumab: Novartis

Canakinumab is an interleukin (IL)-1β blocker indicated to treat certain periodic fever syndromes, such as cryopyrin-associated periodic syndromes and systemic juvenile idiopathic arthritis. Novartis is conducting phase III trial, called CAN-COVID which will evaluate the drug’s efficacy in treating a type of severe immune overreaction called cytokine release syndrome (CRS) related to Covid-19 pneumonia.

Discover more about the emerging Cytokine Release Syndrome drugs @ Cytokine Release Syndrome Treatment Drugs

Cytokine Release Syndrome Key Companies

  • Novartis
  • Incyte Corporation
  • Olatec Therapeutics LLC
  • And others

Cytokine Release Syndrome Pipeline Therapies

  • Canakinumab
  • Itacitinib
  • Dapansutrile
  • And others

Cytokine Release Syndrome Pipeline Therapeutics Assessment

  • By development stage
  • By product type
  • By route of administration
  • By molecule type
  • By MOA type 

Scope of the Cytokine Release Syndrome Pipeline Report 

  • Coverage: Global 
  • Key Cytokine Release Syndrome Companies: Novartis, Incyte Corporation, Olatec Therapeutics LLC, and others
  • Key Cytokine Release Syndrome Pipeline Therapies: Canakinumab, Itacitinib, Dapansutrile, and others

Find out more about the Cytokine Release Syndrome treatment options in development @ Cytokine Release Syndrome Clinical Trials

Table of Contents

1. Introduction

2. Executive Summary

3. Overview

4. Pipeline Therapeutics

5. Late-Stage Products (Phase III)

6. Mid-Stage Products (Phase  II)

7. Early Stage Products (Phase  I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. Therapeutic Assessment

11. Inactive Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. Unmet Needs

14. Market Drivers and Barriers

15. Appendix

16. About DelveInsight

Request for a sample report to know more about the leading companies in the Cytokine Release Syndrome pipeline segment.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles